Rare complex mutational profile in an ALK inhibitor-resistant non-small cell lung cancer

Anticancer Research

Volumn 35, Issue 5, 2015, Pages 3007-3012

  Azzato, Elizabeth M ^a   Deshpande, Charuhas ^a   Aikawa, Vania ^a   Aggarwal, Charu ^a   Alley, Evan ^a   Jacobs, Benjamin ^a   Morrissette, Jennifer ^a   Daber, Robert ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ALK inhibitor; ALK translocation; ATM; Case report; Crizotinib resistance; Genomics; KRAS; Next generation sequencing; Non small cell lung cancer; STK11

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ATM PROTEIN; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PACLITAXEL; PEMETREXED; PROTEIN KINASE LKB1; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RAS PROTEIN; STK11 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; AGED; AORTOPULMONARY SEPTAL DEFECT; ARTICLE; BRACHYTHERAPY; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CATARACTOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DNA PROBE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXON; FRAMESHIFT MUTATION; HUMAN; HUMAN TISSUE; LASER SURGERY; LOBECTOMY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; NEXT GENERATION SEQUENCING; OPHTHALMOLOGY; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; SMOKING; SYSTEMIC THERAPY; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENE REARRANGEMENT; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84929674605     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. http://www.who.int/mediacentre/factsheets/fs297/en/ (Accessed on 2/28/15)
2. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE and Yang SC, NCCN Non-Small Cell Lung Cancer Panel Members: Non-small cell lung cancer. J Natl Compr Canc Netw 8(7): 740-801, 2010.
3. Cardarella S and Johnson BE: The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 188(7): 188: 770-775, 2013.
4. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E and Ladanyi M: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8(7): 823-859, 2013.
5. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA and Settleman J: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68(9): 3389-3395, 2008.
6. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and Giaccone G: American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29(15): 2121-2127, 2011.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10): 947-957, 2009.
8. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC and Mok TS: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21): 2866-2874, 2011.
9. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y and Mano H: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153): 561-566, 2007.
10. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW and Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18): 1693-1703, 2010.
11. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ and Iafrate AJ: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26): 4247-4253, 2009.
12. Martin P, Leighl NB, Tsao M-S and Shepherd FA: KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 8(5): 530-542, 2013.
13. Roberts PJ and Stinchcombe TE: KRAS mutation: Should we test for it, and does it matter? J Clin Oncol 31(8): 1112-1121, 2013.
14. Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA, and Rosell R: KRAS mutations in lung cancer. Clin Lung Cancer 14(3): 205-214, 2013.
15. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF and Ladanyi M: Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18(22): 6169-6177, 2012.
16. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D and Shaw AT: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19(15): 4273-4281, 2013.
17. Stella GM, Scabini R, Inghilleri S, Cemmi F, Corso S, Pozzi E, Morbini P, Valentini A, Dore R, Ferrari S, Luisetti M and Zorzetto M: EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol 139(8): 1327-1335, 2013.
18. Arcila ME, Lau C, Jhanwar S, Zakowski M, Kris M and Ladanyi M: Comprehensive analysis for clinically relevant oncogenic driver mutations in 1131 consecutive lung adenocarcinomas. Mod Pathol 24(1 Suppl.): 404A, abstract 1721, 2011.
19. The Cancer Genome Atlas Research Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407): 330-337, 2012.
20. Weidlich S, Walsh K, Crowther D, Burczynski ME, Feuerstein G, Carey FA, Steele RJ, Wolf CR, Miele G and Smith G: Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Br J Cancer 105(2): 246-254, 2011.
21. Mancini I, Santucci C, Sestini R, Simi L, Pratesi N, Cianchi F, Valanzano R, Pinzani P and Orlando C: The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. J Mol Diagn 12(5): 705-711, 2010.
22. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M and Orlando C: High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130(2): 247-253, 2008.
23. Bläker H, Helmchen B, Bönisch A, Aulmann S, Penzel R, Otto HF and Rieker RJ: Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. Scand J Gastroenterol 39(8): 748-753, 2004.
24. Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, Palmi C, Carta C, Pession A, Aricò M, Masera G, Basso G, Sorcini M, Gelb BD and Biondi A: Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104(2): 307-313, 2004.
25. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62(22): 6451-6455, 2002.
26. Tsukuda K, Tanino M, Soga H, Shimizu N and Shimizu K: A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 278(3): 653-658, 2000.
27. Gremer L, Merbitz-Zahradnik T, Dvorsky R, Cirstea IC, Kratz CP, Zenker M, Wittinghofer A and Ahmadian MR: Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat 32(1): 33-43, 2011.
28. Gill RK, Yang SH, Meerzaman D, Mechanic LE, Bowman ED, Jeon HS, Roy Chowdhuri S, Shakoori A, Dracheva T, Hong KM, Fukuoka J, Zhang JH, Harris CC and Jen J: Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 30(35): 3784-3791, 2011.
29. Launonen V: Mutations in the human LKB1/STK11 gene. Hum Mutat 26(4): 291-297, 2005.
30. Sanchez-Cespedes M: The role of LKB1 in lung cancer. Fam Cancer 10(3): 447-453, 2011.
31. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Jänne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE and Wong KK: LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155): 807-810, 2007.
32. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M and Wilson RK: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216): 1069-1075, 2008.
33. Greulich H: The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer 1(12): 1200-1210, 2010.
34. Campos-Gomez S, Lara-Guerra H, Routbort MJ, Lu X and Simon GR: Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. Int J Biol Markers Dec 23: 0, 2014.
35. Rossi G, Baldi L, Barbieri F, Bertolini F and Tiseo M: Concomitant EGFR and KRAS mutations in ALK rearranged lung cancer. Ann Oncol Feb 10: 0, 2015.
36. Homa I, Sawicki M, Wojas-Krawczyk K, Nicö M, Mlak R, Powrózek T, Krawczyk P, Przybylski P, Czekajska-Chehab E, and Milanowski J: Rare co-existence of mutation in KRAS and ALK gene re-arrangement in an adenocarcinoma patient - a case report. Anticancer Res 34(7): 3701-3705, 2014.
37. Perez CA, Velez M, Raez LE and Santos ES: Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation. Lung Cancer 84(2): 110-115, 2014.